(Image: Shutterstock)
February 6, 2023 03:14 PM ESTUpdated 03:28 PM
Bioregnum
R&D

A long­time track­er on phar­ma R&D pro­duc­tiv­i­ty takes a post-pan­dem­ic plunge back to a bleak re­al­i­ty

John Carroll

Editor & Founder

So much for the “turn­around.”

The bio­phar­ma in­dus­try tossed the old play­book on R&D, broke every rule and bent every trend dur­ing the pan­dem­ic. Some …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

Corvus' ear­ly-phase atopic der­mati­tis da­ta prompt stock ral­ly

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times